HIV-related lymphomas
- PMID: 35900752
 - DOI: 10.1097/CCO.0000000000000890
 
HIV-related lymphomas
Abstract
Purpose of review: To summarize the recent evidence on the pathology, current standard of care and recent advances in the treatment of HIV-related lymphomas.
Recent findings: Lymphomas remain a major cause of morbidity and mortality in people living with HIV, even in the era of combination antiretroviral therapy (cART). However, treatment outcomes for these malignancies have improved in recent decades, due to full-dose chemotherapy, effective cART and supportive care. Recent advances include the identification of novel driving signaling pathways as promising molecular targets to improve lymphoma outcomes.
Summary: Patients with HIV-related lymphomas who receive effective cART should be treated like the general population.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
References
- 
    
- Cesarman E, Chadburn A, Rubinstein PG. KSHV/HHV8-mediated hematologic diseases. Blood 2022; 139:1013–1025.
 
 - 
    
- Toner K, Bollard CM. EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target. Blood 2022; 139:983–994.
 
 - 
    
- Carbone A, Vaccher E, Gloghini A. Hematologic cancers in individuals infected by HIV. Blood 2022; 139:995–1012.
 
 - 
    
- Kimani SM, Painschab MS, Horner MJ, et al. Epidemiology of haematological malignancies in people living with HIV. Lancet HIV 2020; 7:e641–e651.
 
 - 
    
- Poizot-Martin I, Lions C, Allavena C, et al. Spectrum and incidence trends of AIDS- and Non-AIDS-defining cancers between 2010 and 2015 in the French Dat’AIDS cohort. Cancer Epidemiol Biomarkers Prev 2021; 30:554–563.
 
 
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
